Major depression
Conditions
Interventions
Trade Name: Cipralex
Product Name: Escitalopram
Product Code: Lu 26-054
Pharmaceutical Form: Tablet
INN or Proposed INN: ESCITALOPRAM
Trade Name: Seropram
Pharmaceutical Form: Tablet
INN or Proposed
Sponsors
Siegfried KASPER, O.Univ.Prof.Dr.Dr.h.c., Medizinische Universität Wien
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Male or female • Age 18 – 55 years • DSM-IV diagnosis of major depression • A score of 16 or greater on the 17-item HAM-D • Signed informed consent form • Negative urine pregnancy test in women at the screening visit and PET days. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Concomitant major medical or neurological illness • Clinically relevant abnormalities on a general physical examination and routine laboratory screening • Current substance abuse • Use of SSRIs or other drugs with affinity to SERT within last 3 months (or use of fluoxetine within last 4 months) • Any exposure to artificial radiation within 6 months prior to the inclusion into the present study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: ;Primary end point(s): ;Main Objective: Verification of higher occupancy of escitalopram compared to citalopram on the serotonin transporter in patients in vivo using equal treatment doses of the S-enantiomer. The main hypothesis is that the SERT occupancy is significantly higher by escitalopram compared to citalopram in patients in vivo after multiple doses. | — |
Countries
Austria
Outcome results
None listed